Evidence map›Paper›PMID 42225671›Full record

ArticleBlood cancer journal2026

Prognostic impact of morphological lymphocyte counts on aggressive adult T-cell leukemia/lymphoma: Japan ATL nationwide registry analysis.

Koji Jimbo, Ayumu Ito, Erika Horibe, Naoko Yagishita, Junya Makiyama, Hidehiro Itonaga, Takayoshi Miyazono, Kisato Nosaka, Makoto Yoshimitsu, Ilseung Choi and 8 more

Abstract read
In one paragraph

Article in Blood cancer journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors.

Koji JimboDivision of Hematopoietic Disease Control, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan.ORCID http://orcid.org/0000-0002-2031-7385
Ayumu ItoDepartment of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
Erika HoribeDepartment of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kanagawa, Japan.ORCID http://orcid.org/0009-0008-7830-5281
Naoko YagishitaDepartment of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kanagawa, Japan.
Junya MakiyamaDepartment of Hematology, Sasebo City General Hospital, Nagasaki, Japan.
Hidehiro ItonagaTransfusion and Cell Therapy Unit, Nagasaki University Hospital, Nagasaki, Japan.
Takayoshi MiyazonoDepartment of Hematology, Imamura General Hospital, Kagoshima, Japan.
Kisato NosakaDepartment of Hematology, Rheumatology and Infectious Diseases, Kumamoto University Hospital, Kumamoto, Japan.
Makoto YoshimitsuDepartment of Hematology and Rheumatology, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan.ORCID http://orcid.org/0000-0002-5935-0385
Ilseung ChoiDepartment of Hematology and Cell Therapy, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Noriaki KawanoDepartment of Internal Medicine, Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan.
Ki-Ryang KohDepartment of Hematology, Osaka General Hospital of West Japan Railway Company, Osaka, Japan.
Eiichi OtsukaDepartment of Hematology, Oita Prefectural Hospital, Oita, Japan.
Hidetoshi NakashimaDepartment of Hematology, Ikeda Hospital, Kagoshima, Japan.
Yoshihisa YamanoDepartment of Rare Diseases Research, Institute of Medical Science, St. Marianna University School of Medicine, Kanagawa, Japan.ORCID http://orcid.org/0000-0001-7527-0345
Yasuhito NannyaDivision of Hematopoietic Disease Control, The Institute of Medical Science, The University of Tokyo, Tokyo, Japan. ynanya@ims.u-tokyo.ac.jp.
Takahiro FukudaDepartment of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital, Tokyo, Japan.
Japan Aggressive ATL Consortium

Funding

Japan Agency for Medical Research and Development (AMED) JP25ck0106860h0003Japan Agency for Medical Research and Development (AMED) JP25fk0108671s1003Japan Agency for Medical Research and Development (AMED) JP25fk0108672h0003Japan Agency for Medical Research and Development (AMED) JP26ck0106860h0004Japan Agency for Medical Research and Development (AMED) JP26fk0108733s0602Japan Agency for Medical Research and Development (AMED) JP26fk0108738s0301Japan Agency for Medical Research and Development (AMED) JP26fk0108759MEXT | Japan Society for the Promotion of Science (JSPS) 25K19568
6 · The paper itself

Abstract

Adult T-cell leukemia/lymphoma (ATL) is a lymphoid malignancy with poor prognosis. Although an increased tumor burden and impaired host immunity are recognized as adverse prognostic factors for aggressive ATL, the prognostic significance of morphologically normal and abnormal peripheral blood lymphocyte counts at the time of diagnosis has not been clarified. We analyzed 638 patients newly diagnosed with aggressive ATL enrolled since 2021 in a nationwide prospective registry across 152 Japanese institutions. Cutoff values derived from receiver operating characteristic curves for survival outcomes identified 860/μL for normal lymphocytes and 15,000/μL for abnormal lymphocytes. Patients with low normal lymphocyte counts had significantly poorer overall survival (OS; P < 0.001) and progression-free survival (PFS; P < 0.001) than those with higher counts. Elevated abnormal lymphocyte counts were significantly associated with shorter PFS (P = 0.004), but not OS (P = 0.496). In multivariate analyses incorporating eight established prognostic factors, a low normal lymphocyte count remained an independent predictor of shorter OS and PFS, whereas a high abnormal lymphocyte count independently predicted shorter PFS. These findings demonstrate that normal and abnormal lymphocyte counts are routinely measured, inexpensive, and rapidly available parameters, highlighting their value as practical and informative prognostic indicators of aggressive ATL.

Indexed as

Leukemia-Lymphoma, Adult T-CellAdultAgedAged, 80 and overFemaleHumansJapanLymphocyte CountMaleMiddle AgedPrognosisRegistries

Identifiers

PMID42225671
PMCPMC13438651

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.